Invention Grant
![6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity](/docs/US/2021-09-07/US11111253B2/abs.jpg.600x600.jpg)
- Patent Title: 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity
-
Application No.: US16846089Application Date: 2020-04-10
-
Publication No.: US11111253B2Publication Date: 2021-09-07
- Inventor: Donna M. Huryn , Peter Wipf , Jennifer Rubin Grandis , Matthew G. LaPorte , Paul A. Johnston , Mark E. Schurdak , Raffaele Colombo
- Applicant: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
- Applicant Address: US PA Pittsburgh
- Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
- Current Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
- Current Assignee Address: US PA Pittsburgh
- Agency: Foley & Lardner LLP
- Main IPC: C07D513/04
- IPC: C07D513/04 ; A61P35/00
![6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity](/abs-image/US/2021/09/07/US11111253B2/abs.jpg.150x150.jpg)
Abstract:
Compounds that selectivity inhibit the STAT3 pathway and not the STAT1 pathway and exhibit anti-proliferative activity are disclosed. Also disclosed are methods of treatment of cancers that are characterized by overexpression of STAT3, which are safer that other therapies.
Public/Granted literature
Information query
